Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic
Tuesday, March 14 • 14:50 - 16:50
Challenges of outsourcing

Sign up or log in to save this to your schedule and see who's attending!

Feedback form is now closed.

The general trend of outsourcing in the pharmaceutical industry did not stop at sample and compound management area. While that key component of early drug discovery was formerly kept within the pharma companies the more recent developments indicate changes in strategy.

Aspects driving decisions to externalize compound management efforts and challenges connected to that will be discussed. Topics highlighted cover strategic considerations, investments and expertise but also the question whether outsourced compound management can provide services of highest quality within turnaround times as internal facilities can do. We will get insight from various angles with the experience of outsourcing pharma companies and the perspective of research organizations providing such services.

14.50 Olivier Casamitjana 
Challenges of outsourcing

The general trend of outsourcing in the pharmaceutical industry did also expanded to sample and compound management area. While that key component of early drug discovery was formerly kept within the pharma companies, because it was considered as an internal asset, a family jewel. The more recent developments indicate changes in strategy, affecting all companies’ types (big pharma, mid-size pharma, virtual biotech).Multiple aspects discussed in the session suggest considering such externalization efforts but also challenges connected to outsourcing will be highlighted. Those refer always to investments and expertise but also the question whether outsourced compound management can provide services of same quality within turnaround times as internal facilities can do. In the same time, building an internal Compound management costs a lot and does not allow an easy return of investment, rather than outsourcing gives this advantage. In the end, the key questions become again how to build the trust? How to build the transition phase to become partners? Moreover, to do a Pros/cons analysis to convince the management…I will get insight from various angles including the experience of outsourcing pharma companies but also the perspective of research organizations providing such services.

15.20 Rose Gonzales
Evaluation of Resourcing Options for Compound Management Workflows

An extensive evaluation of resourcing options was conducted for a discrete set of compound management workflows focused on the stewardship of Pfizer's compound collection.  The resourcing options considered were: (1) Transfer to a third party, (2) In house management through contingent workers, (3) Insourcing through a dedicated third  party on site in Groton.  This presentation will go through the information gathering, analysis, recommendations, and decisions taken.  Finally, a review of current state of implementation 12 months post decision will also be presented.

15.50 Elizabeth Admirand
Ensuring Data Quality in an Outsourcing Environment:How Epizyme Conducted Detailed CRO Site Checks ona Global Scale

In an effort to reduce costs, the outsourcing community is seeing an increase in business. For Epizyme, nearly 70% ofresearch is being conducted at Contract Research Organizations. In this talk, we discuss how fine tuning outsourcedsite processes has ensured data integrity during tech-transfers. Conducting site checks around the world has aided inthe understanding of varied capabilities of different contract partners, allowing us to manage internal and externalexpectations accordingly. By establishing sample handling guidelines through written and in-person communication,Epizyme has unearthed key red flags to look for in order to maintain a high level of quality.

16.20 Ludovic Otterbein
Outsourcing of Early Discovery Processes

A large proportion of Lundbeck’s Research budget is allocated to external collaborations around the world. These sets of strategic initiatives have an impact on the internal operating models for early and late discovery. From chemistry to compound management and screening, we have defined outsourcing models based on different drivers: capacity, capability, flexibility & cost in order to support our research ambitions. This presentation will highlight our current operating models for early discovery, the rationale and also the complexity &challenges associated.

Moderators
avatar for Dirk Winkler

Dirk Winkler

VP Biophysics and Compound Management, EVOTEG AG
Dirk Winkler is in charge of Biophysics and Compound Management at Evotec AG, Hamburg, Germany. After receiving his Ph.D. from the University of Leipzig, Germany he started his industrial career in 1998 at Evotec. In his current role Dirk is also responsible for Evotec’s screening library, including various aspects of compound handling as well as library maintenance and improvement. Based on his background as an organic chemist he is... Read More →

Speakers
EA

Elizabeth Admirand

?, Epizyme
Elizabeth has been working in the Lead Discovery group at Epizyme for the past 4.5 years with a primary focus inCompound Management and Biochemistry. Applying her knowledge of compound management, biochemistry, andinformatics, Elizabeth has been able to successfully conduct diligence checks at multiple CROs and aid in the decisionto initiate work with new partners. Elizabeth was previously employed at Proteostasis Therapeutics in Cambridge... Read More →
avatar for Olivier Casamitjana

Olivier Casamitjana

Senior VP, Global Compound Management Head, EVOTEC France
Engineer by training in biological sciences, Olivier Casamitjana acquired more than 18 years of experience in the pharmaceutical industry. Successively at Pfizer and then Solvay-Fournier, Olivier worked in the domains of assay development, high throughput screening and management of sample patrimony. Then Olivier worked within Sanofi during 10 years. He was successively project leader of large automated stores for compound management and of a... Read More →
avatar for Rosalia Gonzales

Rosalia Gonzales

Director, Pfizer, Inc.
Rose Gonzales is Director of Compound Management & Distribution (CMD) at Pfizer Worldwide Research & Development, based in Groton, CT.   She has been at Pfizer for 17 years, the last 7 in her current role overseeing the compound collection of Pfizer.  Rose has undergraduate and graduate degrees in Chemicial Engineering; her PhD thesis was in the area of cell adhesion under low shear stress conditions.  Previous to... Read More →
avatar for Ludovic Otterbein

Ludovic Otterbein

Director Research Informatics, Lundbeck
In charge of Research Informatics, Compound Management and Analytical Chemistry within Lundbeck, I focus on setting the strategic direction of the group and its implementation. | Our compound management area receives, manages and delivers compounds to the entire research organisation using optimized processes and state of the art automation. We have in the last few years internalize the management of our liquid collection after few years of... Read More →


Tuesday March 14, 2017 14:50 - 16:50
Music Hall 1